ARC Medical Inc. Completes $3 Million Financing for Clinical Trials
Deal News | Nov 19, 2024 | EIN
ARC Medical Inc., a company specializing in surgical adhesion prevention, has successfully raised $3 million in funding to support upcoming clinical trials. The financing will enable the company to initiate trials for its JOCOAT and IPCOAT liquid medical devices aimed at preventing orthopedic, gynecological, and abdominal surgical adhesions. The trials include the evaluation of the JOCOAT device for patients undergoing anterior cruciate ligament (ACL) repair surgery and the IPCOAT device for gynecological surgery related to endometriosis. The company also aims to expand discussions for a partnership in Japan, where adhesion prevention devices are in demand. ARC Medical's products, backed by clinical data and multiple patents, offer a promising solution to a significant post-surgical complication that could benefit millions of patients in the US and globally.
Sectors
- Medical Devices
- Biotechnology
Geography
- Canada – ARC Medical Inc. is based in Vancouver, British Columbia, where the company is headquartered and operates.
- United States – The US is a primary market for ARC Medical's devices, with significant patient populations undergoing surgeries that could benefit from their products.
- Japan – ARC Medical is exploring partnership opportunities in Japan due to the substantial number of surgical procedures performed annually that involve adhesion prevention.
Industry
- Medical Devices – The article discusses ARC Medical Inc., which develops liquid medical devices aimed at preventing surgical adhesions.
- Biotechnology – ARC Medical's innovation in adhesion prevention represents a significant advancement in biotechnology designed to tackle post-surgical complications.
Financials
- USD $3 Million – The amount raised by ARC Medical to support clinical trials for its JOCOAT and IPCOAT devices.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| ARC Medical Inc. | Target/Bidding Company | Company | A company specializing in surgical adhesion prevention that recently raised $3 million to advance clinical trials for its devices. |
| Dr. Chris Springate | CEO of ARC Medical Inc. | Person | Chief Executive Officer of ARC Medical, overseeing the development and financing strategies of the company. |
| Prof. Dr. Robert Litchfield | Chief Medical Officer | Person | Leads the JOCOAT Orthopedic Clinical Trial and is an experienced orthopedic surgery investigator. |
| Prof. Dr. Rudy De Wilde | Clinical Trial Lead | Person | Key opinion leader in gynecological surgical adhesion reduction, leading the IPCOAT Gynecological Clinical Trial. |
| Ray Jordan | Chief Corporate Affairs Officer | Person | Responsible for corporate communications and partnership inquiries at ARC Medical. |